) reported second quarter earnings per share of $2.29 (including
the impact of stock-based compensation expense), well above the
Zacks Consensus Estimate of $1.83 and 25.8% above the year-ago
earnings. Second quarter 2013 revenues increased 21% to $1.7
billion. Revenues were well above the Zacks Consensus Estimate of
$1.6 billion. Newly launched multiple sclerosis (MS) drug,
Tecfidera, drove second quarter results.
Including one-time items, second quarter 2013 earnings
increased 28% to $2.06 per share.
The Quarter in Detail
Second quarter Tysabri revenues increased 38% to $387 million
from the year-ago period. Biogen is now booking 100% of Tysabri
revenues following its acquisition of
) rights in Tysabri. Global in-market net revenues of Tysabri
came in at $387 million (down 2%) in the second quarter of
Tysabri global revenues consisted of U.S. revenues of $218
million and ROW (Rest of the World) revenues of $169 million.
Revenues declined on a sequential basis.
Meanwhile, Avonex, Biogen's lead MS product, posted second
quarter revenues of $774 million (up 2%). On a sequential basis,
Avonex revenues were up 3.8%. Avonex revenues in ex- U.S. markets
were $295 million.
Biogen has been working on driving Avonex revenues. The
company launched Avonex Pen in the U.S. last year. Avonex Pen
helps improve convenient administration. The rollout of Avonex
Pen in the EU and U.S. should increase patient and physician
interest in Avonex.
Rituxan revenues grew 1% to $289 million in the second
Tecfidera, the latest offering from Biogen's MS portfolio, is
off to a strong start with sales coming in at $192 million. This
includes patient demand (approximately $110 million) as well as
inventory stocking (approximately $82 million) at wholesaler and
specialty pharmacy levels. Biogen had launched Tecfidera in early
Apr in the U.S.
Raises Guidance Again
Biogen raised its guidance yet again for 2013. The company now
expects earnings in the range of $8.25 - $8.50 per share on
revenue growth of 22% - 23%. The company was previously expecting
earnings in the range of $7.80 - $7.90 per share on revenue
growth of 16% - 18%. The Zacks Consensus Estimate currently
stands at $8.00 per share. With Biogen raising its guidance, we
expect significant upward revisions in estimates.
The company maintained its SG&A guidance of 24% to 26% of
total revenues but tweaked its R&D guidance to 21% to 23% of
total revenues (old guidance: 22% to 23% of total revenues).
Biogen started 2013 on a strong note with better-than-expected
earnings and revenues and the momentum continues with second
quarter earnings beating expectations by a wide margin. Results
were primarily driven by the strong performance of Tecfidera. We
are also positive on Biogen's gaining full control over Tysabri.
Key products, Avonex and Tysabri, should continue contributing
significantly to sales. Tecfidera should help drive long-term
growth. Biogen has several development and regulatory catalysts
coming up in the next few quarters. With Tecfidera launched, we
expect investor focus to remain on its commercialization and
sales ramp up.
Biogen currently carries a Zacks Rank #3 (Hold). Shares were
up in pre-market trading. At present, companies like
) look well-positioned. While Actelion is a Zacks Rank #1 (Strong
Buy) stock, Amgen is a Zacks Rank #2 (Buy) stock.
ACTELION LTD (ALIOF): Get Free Report
AMGEN INC (AMGN): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
ELAN CP PLC ADR (ELN): Free Stock Analysis
To read this article on Zacks.com click here.